DR. JEAN-PAUL KRESS
Chief Executive Officer
Year of Birth 1965
Management Board Member of MorphoSys AG since 2019
End of appointment 2021
Dr. Jean-Paul Kress joined MorphoSys in September 2019. Prior to joining MorphoSys, he served as President and Chief Executive Officer of Syntimmune (now Alexion). Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a strong track record of commercial, operational and business development leadership in various senior management roles in North America and Europe. Among other assignments, he acted as Executive Vice President and Head of Global Therapeutic Operations at Biogen and Senior Vice President, Head of North America at Sanofi Genzyme. Previously, he was Chief Executive Officer of Sanofi Pasteur MSD, and gained further experience in positions at Gilead, Abbvie and Eli Lilly.
Dr. Kress received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in pharmacology and immunology from École normale supérieure in Paris.